# Giorgio Raimondi

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 47 papers | 2,572 citations | 23 h-index | 50 g-index |
| 63 ext. papers | 2,806 ext. citations | 5.4 avg, IF | 4.74 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 47 | Immunoregulatory functions of mTOR inhibition. *Nature Reviews Immunology*, **2009**, 9, 324-37 | 36.5 | 638 |
| 46 | Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. *Journal of Immunology*, **2007**, 178, 7018-31 | 5.3 | 358 |
| 45 | Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. *Journal of Immunology*, **2006**, 176, 2808-16 | 5.3 | 135 |
| 44 | Low TLR4 expression by liver dendritic cells correlates with reduced capacity to activate allogeneic T cells in response to endotoxin. *Journal of Immunology*, **2005**, 174, 2037-45 | 5.3 | 135 |
| 43 | "Alternatively activated" dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. *Journal of Immunology*, **2006**, 177, 5868-77 | 5.3 | 129 |
| 42 | High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. *Transplantation*, **2008**, 85, 369-77 | 1.8 | 121 |
| 41 | Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. *Journal of Immunology*, **2010**, 184, 624-36 | 5.3 | 80 |
| 40 | IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. *Journal of Immunology*, **2012**, 188, 5227-37 | 5.3 | 77 |
| 39 | Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. *Transplant Immunology*, **2008**, 18, 307-18 | 1.7 | 72 |
| 38 | Controlled release formulations of IL-2, TGF-1 and rapamycin for the induction of regulatory T cells. *Journal of Controlled Release*, **2012**, 159, 78-84 | 11.7 | 68 |
| 37 | Donor age negatively affects the immunoregulatory properties of both adipose and bone marrow derived mesenchymal stem cells. *Transplant Immunology*, **2014**, 30, 122-7 | 1.7 | 62 |
| 36 | Naturally occurring regulatory T cells: recent insights in health and disease. *Critical Reviews in Immunology*, **2007**, 27, 61-95 | 1.8 | 61 |
| 35 | Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance. *Journal of Immunology*, **2012**, 188, 3667-77 | 5.3 | 60 |
| 34 | Endotoxin modulates the capacity of CpG-activated liver myeloid DC to direct Th1-type responses. *European Journal of Immunology*, **2006**, 36, 2483-93 | 6.1 | 54 |
| 33 | Human induced pluripotent stem cell-derived models to investigate human cytomegalovirus infection in neural cells. *PLoS ONE*, **2012**, 7, e49700 | 3.7 | 53 |
| 32 | Poor allostimulatory function of liver plasmacytoid DC is associated with pro-apoptotic activity, dependent on regulatory T cells. *Journal of Hepatology*, **2008**, 49, 1008-18 | 13.4 | 52 |
| 31 | Abstract 11: the role of donor antigen persistance in maintaining immune tolerance to a vascularized composite allograft. *Plastic and Reconstructive Surgery*, **2014**, 133, 21 | 2.7 | 47 |

| | | | |
|---|---|---|---|
| 30 | Bioinspired controlled release of CCL22 recruits regulatory T cells in vivo. *Advanced Materials*, **2012**, 24, 4735-8 | 24 | 46 |
| 29 | Induced regulatory T cells: mechanisms of conversion and suppressive potential. *Human Immunology*, **2012**, 73, 328-34 | 2.3 | 39 |
| 28 | Persistent infection by HSV-1 is associated with changes in functional architecture of iPSC-derived neurons and brain activation patterns underlying working memory performance. *Schizophrenia Bulletin*, **2015**, 41, 123-32 | 1.3 | 36 |
| 27 | Induction of peripheral T cell tolerance by antigen-presenting B cells. II. Chronic antigen presentation overrules antigen-presenting B cell activation. *Journal of Immunology*, **2006**, 176, 4021-8 | 5.3 | 27 |
| 26 | Tolerogenic dendritic cell-regulatory T-cell interaction and the promotion of transplant tolerance. *Transplantation*, **2009**, 87, S86-90 | 1.8 | 24 |
| 25 | Dendritic cells,tolerance and therapy of organ allograft rejection. *Contributions To Nephrology*, **2005**, 146, 105-120 | 1.6 | 24 |
| 24 | All-trans retinoic acid and rapamycin synergize with transforming growth factor-β to induce regulatory T cells but confer different migratory capacities. *Journal of Leukocyte Biology*, **2013**, 94, 981-9 | 6.5 | 22 |
| 23 | Induction of peripheral T cell tolerance by antigen-presenting B cells. I. Relevance of antigen presentation persistence. *Journal of Immunology*, **2006**, 176, 4012-20 | 5.3 | 22 |
| 22 | The use of luminex assays to measure cytokines. *Journal of Investigative Dermatology*, **2015**, 135, 1-5 | 4.3 | 18 |
| 21 | Exploring cell-based tolerance strategies for hand and face transplantation. *Expert Review of Clinical Immunology*, **2015**, 11, 1189-204 | 5.1 | 16 |
| 20 | Rhesus monkey immature monocyte-derived dendritic cells generate alloantigen-specific regulatory T cells from circulating CD4+CD127-/lo T cells. *Transplantation*, **2009**, 88, 1057-64 | 1.8 | 10 |
| 19 | Frontiers of immunological tolerance. *Methods in Molecular Biology*, **2007**, 380, 1-24 | 1.4 | 10 |
| 18 | Mechanisms of rejection in vascular composite allotransplantation. *Current Opinion in Organ Transplantation*, **2018**, 23, 28-33 | 2.5 | 9 |
| 17 | Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. *Transplantation*, **2018**, 102, 593-600 | 1.8 | 8 |
| 16 | Orthotopic Hind Limb Transplantation in the Mouse. *Journal of Visualized Experiments*, **2016**, 53483 | 1.6 | 8 |
| 15 | A Novel mTORC1-Dependent, Akt-Independent Pathway Differentiates the Gut Tropism of Regulatory and Conventional CD4 T Cells. *Journal of Immunology*, **2016**, 197, 1137-47 | 5.3 | 7 |
| 14 | Multiphase Assembly of Small Molecule Microcrystalline Peptide Hydrogel Allows Immunomodulatory Combination Therapy for Long-Term Heart Transplant Survival. *Small*, **2020**, 16, e2002791 | 11 | 7 |
| 13 | Type-I Interferons Inhibit Interleukin-10 Signaling and Favor Type 1 Diabetes Development in Nonobese Diabetic Mice. *Frontiers in Immunology*, **2018**, 9, 1565 | 8.4 | 6 |

| | | | |
|---|---|---|---|
| 12 | Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications. *Journal of Visualized Experiments*, **2015**, | 1.6 | 6 |
| 11 | Vascularized composite allotransplantation combined with costimulation blockade induces mixed chimerism and reveals intrinsic tolerogenic potential. *JCI Insight*, **2020**, 5, | 9.9 | 6 |
| 10 | Taming inflammation by targeting cytokine signaling: new perspectives in the induction of transplantation tolerance. *Immunotherapy*, **2014**, 6, 637-53 | 3.8 | 4 |
| 9 | Autoreactive isotype-specific T cells determine B cell frequency. *European Journal of Immunology*, **2001**, 31, 215-24 | 6.1 | 4 |
| 8 | The outstanding questions in transplantation: It's about time. *American Journal of Transplantation*, **2018**, 18, 271-272 | 8.7 | 3 |
| 7 | Combining Theoretical and Experimental Techniques to Study Murine Heart Transplant Rejection. *Frontiers in Immunology*, **2016**, 7, 448 | 8.4 | 2 |
| 6 | Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.. *Pharmaceuticals*, **2021**, 15, | 5.2 | 2 |
| 5 | An Overview of Physiologic Immunity **2014**, 13-29 | | 1 |
| 4 | A short course of tofacitinib sustains the immunoregulatory effect of CTLA4-Ig in the presence of inflammatory cytokines and promotes long-term survival of murine cardiac allografts. *American Journal of Transplantation*, **2021**, 21, 2675-2687 | 8.7 | 1 |
| 3 | Abstract 102: inflammatory mediators modulate alloreactive T cell susceptibility to immune-regulation in reconstructive transplantation. *Plastic and Reconstructive Surgery*, **2014**, 133, 117 | 2.7 | |
| 2 | Ex vivo Expanded Regulatory T cells Combined with Short-term Costimulation Blockade Prevent Rejection of Vascularized Composite Allografts. *Transplantation*, **2018**, 102, S200 | 1.8 | |
| 1 | Modeling the Potential of Treg-Based Therapies for Transplant Rejection: Effect of Dose, Timing, and Accumulation Site.. *Transplant International*, **2022**, 35, 10297 | 3 | |